The most oversold stocks in the healthcare sector offer an opportunity to invest in undervalued companies.
The RSI is a momentum indicator that compares the strength of a stock’s price on days when it has risen to the strength of its price on days when it has fallen. By comparing this with the price movement, traders can get a better idea of how the stock will perform in the short term. When the RSI falls below 30, the asset is usually considered oversold. Benzinga Pro.
Below is a current list of major oversold stocks in this sector with an RSI close to or below 30.
Cassava Science Co., Ltd. Sava
- Cassava Sciences filed a complaint with the U.S. Department of Justice (DOJ) and the U.S. Securities and Exchange Commission (SEC) on July 1 amid ongoing investigations into the company and two of its senior employees. The company’s shares have fallen about 46% in the past five days, hitting a 52-week low of $8.79.
- RSI Values: 14.66
- SAVA Price Trends: Cassava Sciences shares fell 5.2% on Friday to close at $10.22.
- Notifications in Benzinga Pro real-time news feed Latest news on Cassava Science.
Owens and Minor Co. Omi
- On June 24, Owens & Minor appointed Jonathan A. Leon as interim CFO. The company’s shares have fallen about 26% in the past month, with a 52-week low of $12.47.
- RSI values: 15.74
- OMI Price Trends: Owens & Minor shares fell 4% on Friday to close at $12.59.
- Benzinga Pro Charting Tools Owens & Minor helped identify trends in stocks.
Castle Biosciences Co., Ltd. CSTL
- On July 5, Baird analyst Catherine Ramsey maintained her outperform rating and $34 price target on Castle Biosciences. The company’s shares have fallen about 25% over the past month, to a 52-week low of $12.07.
- RSI Values: 17.90
- CSTL Price Action: Castle Biosciences shares fell 18.1% on Friday to close at $17.40.
- Benzinga Pro’s Signals feature has potential CSTL shares surge.
National Research Corporation Nuclear Regulatory Commission
- National Research reported a decline in quarterly sales performance on May 7. CEO Michael Hayes said, “NRC remains strongly positioned for growth in an expanding market. With decades of benchmarking and trusted thought leadership, we provide healthcare insights that few competitors can access. Our customer service is also unmatched, and we continue to roll out innovative new products and technologies.” The company’s shares have fallen about 10% in the past month. The company’s 52-week low is $21.73.
- RSI Values: 19.72
- NRC Price Trends: National Research shares rose 0.2% on Friday to close at $22.99.
- Benzinga Pro’s Earnings Calendar National Research’s upcoming earnings report.
Pasila Biosciences Inc. PCRX
- Pasila Biosciences announced on July 2 that the FDA had approved a generic version of Exparel. The company’s stock price has fallen by about 25% in the past five days. The company’s 52-week low was $20.52.
- RSI Values: 21.16
- PCRX Price Trend: Pasira Biosciences shares fell 2.8% on Friday to close at $21.06.
- Pasila Biosciences insider trading under scrutiny Use Benzinga Pro.
Read more: Top 3 financial stocks you’ll regret missing in Q3
Market news and data provided by Benzinga API
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
